{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:11:14Z","timestamp":1793913074157,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.lungcan.2025.108858","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:01:53Z","timestamp":1764345713000},"page":"108858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non\u2013small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2603-7296","authenticated-orcid":false,"given":"Geoffrey","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Abrahami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3230-7601","authenticated-orcid":false,"given":"Priya","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7627-9519","authenticated-orcid":false,"given":"Nada","family":"Rifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglei","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnan","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneeth","family":"Iyengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1458-0064","authenticated-orcid":false,"given":"Nathan A.","family":"Pennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice T.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2025.108858_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2025.108858_b0010","unstructured":"American Cancer Society, What is lung cancer? https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/what-is.html. (Accessed March 3 2025)."},{"key":"10.1016\/j.lungcan.2025.108858_b0015","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results. Cancer Stat Facts: Lung and Bronchus Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html. (Accessed April 17, 2025)."},{"key":"10.1016\/j.lungcan.2025.108858_b0020","doi-asserted-by":"crossref","unstructured":"G.J. Riely, D.E. Wood, D.S. Ettinger, D.L. Aisner, W. Akerley, J.R. Bauman, A. Bharat, D.S. Bruno, J.Y. Chang, L.R. Chirieac, M. DeCamp, A.P. Desai, T.J. Dilling, J. Dowell, G.A. Durm, S. Gettinger, T.E. Grotz, M.A. Gubens, A. Juloori, R.P. Lackner, M. Lanuti, J. Lin, B.W. Loo, C.M. Lovly, F. Maldonado, E. Massarelli, D. Morgensztern, T.C. Mullikin, T. Ng, D. Owen, D.H. Owen, S.P. Patel, T. Patil, P.M. Polanco, J. Riess, T.A. Shapiro, A.P. Singh, J. Stevenson, A. Tam, T. Tanvetyanon, J. Yanagawa, S.C. Yang, E. Yau, K.M. Gregory, L. Hang, Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw 22(4) (2024) 249-274.","DOI":"10.6004\/jnccn.2204.0023"},{"key":"10.1016\/j.lungcan.2025.108858_b0025","doi-asserted-by":"crossref","unstructured":"D.S. Ettinger, D.E. Wood, D.L. Aisner, W. Akerley, J.R. Bauman, A. Bharat, D.S. Bruno, J.Y. Chang, L.R. Chirieac, T.A. D'Amico, M. DeCamp, T.J. Dilling, J. Dowell, S. Gettinger, T.E. Grotz, M.A. Gubens, A. Hegde, R.P. Lackner, M. Lanuti, J. Lin, B.W. Loo, C.M. Lovly, F. Maldonado, E. Massarelli, D. Morgensztern, T. Ng, G.A. Otterson, J.M. Pacheco, S.P. Patel, G.J. Riely, J. Riess, S.E. Schild, T.A. Shapiro, A.P. Singh, J. Stevenson, A. Tam, T. Tanvetyanon, J. Yanagawa, S.C. Yang, E. Yau, K. Gregory, M. Hughes, Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw 20(5) (2022) 497-530.","DOI":"10.6004\/jnccn.2022.0025"},{"key":"10.1016\/j.lungcan.2025.108858_b0030","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer Version 1.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed November 18, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN, National Comprehensive Cancer Network\u00ae (NCCN\u00ae)."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108858_b0035","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"E.G.C.E.a. clinicalguidelines@esmo.org, Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108858_b0040","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"ALEX Trial investigators, Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108858_b0045","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108858_b0050","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"CROWN trial investigators, first-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108858_b0055","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2025.108858_b0060","article-title":"\\zaAlectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study","author":"Peters","year":"2025","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108858_b0065","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2025.108858_b0070","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","article-title":"The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108858_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108436","article-title":"Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: an observational cohort study","volume":"201","author":"Uprety","year":"2025","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108858_b0080","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108858_b0085","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.cllc.2022.07.008","article-title":"Efficacy and safety of brigatinib compared with crizotinib in asian vs. non-asian patients with locally advanced or metastatic ALK-inhibitor-naive ALK+ non-small cell lung cancer: final results from the phase III ALTA-1L study","volume":"23","author":"Ahn","year":"2022","journal-title":"Clin. Lung Cancer"},{"issue":"29","key":"10.1016\/j.lungcan.2025.108858_b0090","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108858_b0095","unstructured":"Flatiron, Flatiron real-world evidence. https:\/\/flatiron.com\/real-world-evidence\/real-world-data. (Accessed March 6 2025)."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108858_b0100","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1186\/s12885-021-08977-0","article-title":"Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108858_b0105","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11523-023-00973-7","article-title":"ALK inhibitor treatment patterns and outcomes in real-world patients with ALK-positive non-small-cell lung cancer: a retrospective cohort study","volume":"18","author":"Wang","year":"2023","journal-title":"Target. Oncol."},{"key":"10.1016\/j.lungcan.2025.108858_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107919","article-title":"Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer","volume":"195","author":"Bauman","year":"2024","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108858_b0115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cllc.2022.09.007","article-title":"Real-world treatment sequencing, toxicities, health utilities, and survival outcomes in patients with advanced ALK-rearranged non-small-cell lung cancer","volume":"24","author":"Schmid","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108858_b0120","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.lungcan.2018.03.008","article-title":"Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer","volume":"119","author":"Burudpakdee","year":"2018","journal-title":"Lung Cancer"},{"issue":"31","key":"10.1016\/j.lungcan.2025.108858_b0125","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study","volume":"40","author":"Solomon","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108858_b0130","unstructured":"US Food and Drug Administration, FDA approves lorlatinib for metastatic ALK-positive NSCLC. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lorlatinib-metastatic-alk-positive-nsclc. (Accessed March 3 2021)."},{"key":"10.1016\/j.lungcan.2025.108858_b0135","article-title":"Raising the bar for real-world data in oncology: approaches to quality across multiple dimensions","volume":"8","author":"Castellanos","year":"2024","journal-title":"JCO Clin Cancer Inform"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:48:28Z","timestamp":1768816108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225007500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":27,"alternative-id":["S0169500225007500"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108858","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non\u2013small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108858"}}